Copyright Reports & Markets. All rights reserved.

Global Alpha Thalassemia Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Alpha Thalassemia Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Folic Acid
      • 1.4.3 Deferasirox
      • 1.4.4 Deferiprone
      • 1.4.5 Hydroxyurea
    • 1.5 Market by Application
      • 1.5.1 Global Alpha Thalassemia Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Ambulatory Surgical Centers
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Alpha Thalassemia Treatment Market Size
    • 2.2 Alpha Thalassemia Treatment Growth Trends by Regions
      • 2.2.1 Alpha Thalassemia Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Alpha Thalassemia Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Alpha Thalassemia Treatment Market Size by by Players
      • 3.1.1 Global Alpha Thalassemia Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Alpha Thalassemia Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Alpha Thalassemia Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Alpha Thalassemia Treatment Key Players Head office and Area Served
    • 3.3 Key Players Alpha Thalassemia Treatment Product/Solution/Service
    • 3.4 Date of Enter into Alpha Thalassemia Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Alpha Thalassemia Treatment Market Size by Type (2014-2019)
    • 4.2 Global Alpha Thalassemia Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Alpha Thalassemia Treatment Market Size (2014-2019)
    • 5.2 Alpha Thalassemia Treatment Key Players in North America
    • 5.3 North America Alpha Thalassemia Treatment Market Size by Type
    • 5.4 North America Alpha Thalassemia Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Alpha Thalassemia Treatment Market Size (2014-2019)
    • 6.2 Alpha Thalassemia Treatment Key Players in Europe
    • 6.3 Europe Alpha Thalassemia Treatment Market Size by Type
    • 6.4 Europe Alpha Thalassemia Treatment Market Size by Application

    7 China

    • 7.1 China Alpha Thalassemia Treatment Market Size (2014-2019)
    • 7.2 Alpha Thalassemia Treatment Key Players in China
    • 7.3 China Alpha Thalassemia Treatment Market Size by Type
    • 7.4 China Alpha Thalassemia Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Alpha Thalassemia Treatment Market Size (2014-2019)
    • 8.2 Alpha Thalassemia Treatment Key Players in Japan
    • 8.3 Japan Alpha Thalassemia Treatment Market Size by Type
    • 8.4 Japan Alpha Thalassemia Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Alpha Thalassemia Treatment Market Size (2014-2019)
    • 9.2 Alpha Thalassemia Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Alpha Thalassemia Treatment Market Size by Type
    • 9.4 Southeast Asia Alpha Thalassemia Treatment Market Size by Application

    10 India

    • 10.1 India Alpha Thalassemia Treatment Market Size (2014-2019)
    • 10.2 Alpha Thalassemia Treatment Key Players in India
    • 10.3 India Alpha Thalassemia Treatment Market Size by Type
    • 10.4 India Alpha Thalassemia Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Alpha Thalassemia Treatment Market Size (2014-2019)
    • 11.2 Alpha Thalassemia Treatment Key Players in Central & South America
    • 11.3 Central & South America Alpha Thalassemia Treatment Market Size by Type
    • 11.4 Central & South America Alpha Thalassemia Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 GlaxoSmithKline
      • 12.1.1 GlaxoSmithKline Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Alpha Thalassemia Treatment Introduction
      • 12.1.4 GlaxoSmithKline Revenue in Alpha Thalassemia Treatment Business (2014-2019))
      • 12.1.5 GlaxoSmithKline Recent Development
    • 12.2 Novartis AG
      • 12.2.1 Novartis AG Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Alpha Thalassemia Treatment Introduction
      • 12.2.4 Novartis AG Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.2.5 Novartis AG Recent Development
    • 12.3 Bellicum Pharmaceuticals
      • 12.3.1 Bellicum Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Alpha Thalassemia Treatment Introduction
      • 12.3.4 Bellicum Pharmaceuticals Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.3.5 Bellicum Pharmaceuticals Recent Development
    • 12.4 Acceleron Pharma
      • 12.4.1 Acceleron Pharma Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Alpha Thalassemia Treatment Introduction
      • 12.4.4 Acceleron Pharma Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.4.5 Acceleron Pharma Recent Development
    • 12.5 Johnson & Johnson
      • 12.5.1 Johnson & Johnson Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Alpha Thalassemia Treatment Introduction
      • 12.5.4 Johnson & Johnson Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.5.5 Johnson & Johnson Recent Development
    • 12.6 Merck & Co.
      • 12.6.1 Merck & Co. Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Alpha Thalassemia Treatment Introduction
      • 12.6.4 Merck & Co. Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.6.5 Merck & Co. Recent Development
    • 12.7 Gilead Sciences, Inc.
      • 12.7.1 Gilead Sciences, Inc. Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Alpha Thalassemia Treatment Introduction
      • 12.7.4 Gilead Sciences, Inc. Revenue in Alpha Thalassemia Treatment Business (2014-2019)
      • 12.7.5 Gilead Sciences, Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Alpha thalassemia causes due to deficiency or absence of alpha globin chains results in alpha thalassemia which is asymptomatic with general hematologic findings and gains silent carrier status. 
      In 2018, the global Alpha Thalassemia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Alpha Thalassemia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alpha Thalassemia Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      GlaxoSmithKline
      Novartis AG
      Bellicum Pharmaceuticals
      Acceleron Pharma
      Johnson & Johnson
      Merck & Co.
      Gilead Sciences, Inc.
      ...

      Market segment by Type, the product can be split into
      Folic Acid
      Deferasirox
      Deferiprone
      Hydroxyurea

      Market segment by Application, split into
      Hospitals
      Ambulatory Surgical Centers
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Alpha Thalassemia Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Alpha Thalassemia Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Alpha Thalassemia Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now